Communiqués ORIC Pharmaceuticals, Inc. Börse Stuttgart

Actions

4TZ

US68622P1093

Recherche biotechnologique et médicale

Temps réel estimé Tradegate 16:22:48 21/09/2026			Varia. 5j.	Varia. 1 janv.
11,25 ^EUR	+2,49 %		+6,14 %	+59,06 %

15/09	Transcript : ORIC Pharmaceuticals, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 10:00 AM
28/08	Un dirigeant d'Oric Pharmaceuticals cède des actions pour une valeur de 1 053 814 $, selon un récent document de la SEC	MT

Communiqués

07/09	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	AQ
04/09	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	GL
02/09	ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences	GL
07/08	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	GL
03/08	ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates	GL
03/08	ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates	AQ
20/07	ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026	GL
14/07	ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer	GL
02/07	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	GL
05/06	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	GL
27/05	ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences	GL
04/05	ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates	GL
01/05	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	GL
17/04	ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting	GL
03/04	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	GL
31/03	ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile	GL
30/03	ORIC Pharmaceuticals to Report Combination Dose Optimization Data from Phase 1b Trial of Rinzimetostat in Patients with mCRPC	AQ
27/03	ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC	GL
17/03	ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting	GL
06/03	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	GL
23/02	ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates	GL
06/02	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	GL
05/02	ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences	GL
14/01	Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff	PR
12/01	ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones	GL